SP Funds S&P World ex-US ETF(SPWO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
SP Funds S&P World ex-US ETF
SPWO.US
News
View More

FDA Grants Breakthrough Therapy Designation to Novartis Ianalumab for Sjögren’s Disease

Novartis AG has received Breakthrough Therapy designation from the FDA for ianalumab, aimed at treating Sjögren’s disease. This designation is based on phase III trial results indicating its potential to meet significant unmet medical needs. Novartis plans to seek global regulatory approval for ianalumab starting in early 2026, which could make it the first targeted treatment for this autoimmune condition.

Reuters·
US
NVS
+0.83%
DE
NOT
0.00%
Reuters·
US
NVS
+0.83%
DE
NOT
0.00%

Syngenta Adopts SAP AI Solutions To Boost Farming Efficiency

Syngenta has partnered with SAP to integrate AI across its operations, modernizing processes with SAP Cloud ERP to enhance efficiency and innovation in agriculture. The partnership aims to support global agricultural growth and improve decision-making through advanced data analytics. SAP's stock is currently in a bearish trend, trading below key moving averages, with a recent decline of 8.75% over the past year. Traders should monitor key support and resistance levels as the stock shows signs of potential upward movement.

benzinga_article·
US
SAP
-0.95%
benzinga_article·
US
SAP
-0.95%

"Capacity is very tight"! Taiwan Semiconductor's performance guidance exceeds expectations across the board, and capital expenditures will significantly increase over the next three years

Taiwan Semiconductor announced that its capital expenditure plan for 2026 will reach up to $56 billion, a significant increase of 37% compared to the actual expenditure of $40.9 billion in 2025, setting a new historical high for the company. It is expected that Q1 revenue will reach between $34.6 billion and $35.8 billion, exceeding the market consensus expectation of $33.22 billion. The guidance for gross margin and operating margin is also significantly better than analysts' expectations, at 63%-65% and 54%-56%, respectively

Wallstreetcn·
US
TSM
+0.22%
US
SOXL
+4.60%
Wallstreetcn·
US
TSM
+0.22%
US
SOXL
+4.60%

BGI Genomics, Roche roll out diagnostic tests for Alzheimer's in China

BGI Genomics and Roche Diagnostics have launched Alzheimer's diagnostic tests in China to improve access to easier diagnosis and monitoring. BGI's blood test is being used in several cities to assess disease progression, while Roche is working on a test for pTau181 in Boao. These blood tests aim to expedite diagnosis and facilitate access to treatments, contrasting with traditional methods like spinal taps and PET scans. Both companies emphasize that their tests are not standalone diagnostic tools but can aid in early screening and reduce unnecessary investigations.

Reuters·
SZ
300676
-6.85%
US
RHHBY
+0.24%
Reuters·
SZ
300676
-6.85%
US
RHHBY
+0.24%

AZ's $80B revenue target 'very much within reach,' CFO says

AstraZeneca's CFO Aradhana Sarin stated at the J.P. Morgan Healthcare Conference that the company's $80 billion revenue target for 2030 is achievable, especially if they maintain last year's success in phase 3 trials. The oncology portfolio has seen significant growth, with 10 positive phase 3 readouts last year and an increase in late-stage drug opportunities. Analysts' projections for 2030 have risen to match the target. Key products include Imfinzi and Tagrisso, with ongoing trials expected to enhance their market positions. AstraZeneca is also focusing on cardiovascular drugs and navigating drug pricing regulations.

Fiercepharma·
US
AZN
+0.43%
Fiercepharma·
US
AZN
+0.43%
© 2026 Longbridge｜Disclaimer